IFM Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
IFM Therapeutics is a biotechnology research company focused on developing medicines that precisely target the innate immune system, aiming to improve outcomes for people with inflammatory disorders and cancer. Based in Boston, Massachusetts, the organization pursues therapies that influence the body's first line of immune defense, seeking specificity and potential clinical impact. By concentrating on innate immune targets, IFM situates its work within immunology-driven biopharmaceutical research. The company serves patients affected by inflammatory conditions and cancer, offering potential new options where immune modulation may provide benefit. It has collaborated with Novartis to develop therapies that inhibit the cGAS-STING pathway, with the collaboration extended in 2021. Historically, Novartis Pharmaceuticals Corporation acquired IFM Therapeutics, reflecting a strategic relationship within the sector.